Prospects sound for horse gel

Written on the 25 January 2011

APRIL 2010

NATURAL product developer BioProspect has moved one step closer to the production of its horse ulcer treatment paste Giguard, after the successful completion of two major safety studies.

CEO David May, says the trials that took place in Sydney cost $300,000, but he expects approval from the Australian Pesticides and Veterinary Medicines Authority (APVMA) in the next nine months.

Once approved he plans to penetrate the Australian market worth between $2 million and $3 million, which could double if another conifer-based topical gel under development is also approved.

“We are getting Giguard through registration as a natural veterinary health product with a general claim of gastro-intestinal well-being,” he says.

“Part of the strategy of registering with the ATVMA is that you get a free sales certificate, so once registered in Australia we can go to countries like the United Arab Emirates (UAE) where it’s a prerequisite to hold a certificate from the country of origin.

“This opens potential for an export strategy, as we want to sell our product on a global scale.”

The trials started last year, covering a five month period with more than 30 horses, following a smaller case study in Sharjah, UAE in 2008.

Giguard is made from conifer by-products from the Russian forestry industry and is used to treat equine gastric ulcer syndrome (EGUS).

May says eight horses died during the trials, but they were control horses who did not use the product and died of natural causes.

“For instance, one died from a snake bite and another ran into a fence and we had to put it down, but that didn’t affect the trial – they were destined for the knackery anyway,” he says.


Latest News

CROMWELL CALLS FOR FULL DISCLOSURE FROM INVESTA

CROMWELL Property Group (ASX:CRM) has claimed Investa Office Fund (ASX:IOF) has not disclosed material information ab...

FRAUD CAUSES SILVER CHEF PROFIT SLIDE

EQUIPMENT financier Silver Chef (ASX:SIV) has seen its half-year profit slide due to fraud.

The Brisbane company r...

MEGAPORT QUADRUPLES REVENUE AND INVESTS IN EXPANSION

MEGAPORT (ASX: MP1) increased revenue 345 per cent to $4.46 million in the six months to 31 December 2016, the com...

IN-STORE VETS BOOST GREENCROSS' PROFIT

GREENCROSS Limited (ASX: GXL) shares lifted 5 per cent in trading today after the Brisbane-based company posted a ...

Related News

WHY EMPLOYEE-OWNED COMPANIES ARE BEATING ASX200 SHARE PRICES

EMPLOYEE-owned companies command a higher share price than their publicly listed peers, reaping a 17 per cent prem...

RISE OF THE MACHINES HAS WORKERS SWEATING

UP TO 3.8 million Australian workers are fearful their job may soon be terminated by a robot, a new survey has shown....

LESS TALK, MORE SMALL BUSINESS ACTION IN 2017

THE future growth and prosperity of Australian SMEs could be undermined if governments lose sight of the sector...

TEST DRIVE A POST GRAD AT BOND

THERE'S only one way to really move your career into the fast lane, says Bond University, and 'test driving...

Contact us

Email News Update Sign Up Contact Details
Subscriptions

PO Box 2087
Brisbane QLD 4001

LoginTell a FriendSign Up to Newsletter